CompanyTCRXNasdaqWaltham, MA

TScan Therapeutics, Inc.

TScan develops TCR-engineered T cell therapies for cancer.

SEC EDGAR ClinicalTrials.gov tscan.com

8-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

TScan Therapeutics sets separation terms for outgoing CFO and CMO

Sep 30PeopleTScan Therapeutics, Inc.

TScan cuts 75% of staff, pauses ALLOHA-2 to focus on in vivo solid tumor program

Sep 2Clinical readoutTScan Therapeutics, Inc.

August 2026

Amgen terminates Crohn's disease collaboration with TScan Therapeutics

Aug 18PartnershipAmgen TScan Therapeutics, Inc.

TScan doses first patient in Phase 3 heme trial, cites Cohort C manufacturing data

Aug 12Quarterly updateTScan Therapeutics, Inc.

July 2026

TScan Therapeutics registers Phase 3 trial of TSC-101 for AML and MDS transplant patients

Jul 14Trial updateTSC-101 TScan Therapeutics, Inc.